Vendor Intelligence Report: Oasis Peptides

Published 13 Jun 2026. 25-page investigative report on who is behind Oasis Peptides: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 3 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Oasis Peptides is a young, uneven vendor, not a uniform avoid. Across 20 Finnrick lab tests, 13 pass and 7 fail, for an overall pass rate of 65%. The signal is product-specific: Retatrutide is the relative strength, making Oasis more plausible there than for CJC-1295 or BPC-157; stricter grading shifts the picture in the full charts.

Oasis Peptides and Oasis Labs resolve to the same commercial operation, and the business file has an age-and-identity problem. The vendor's own terms, Nevada formation records, certificate logs, and archived captures do not line up with a simple 2023-founded narrative. Trustpilot merge artifacts point toward a predecessor or rebrand, but the earlier identity remains unresolved.

COA integrity is the central verification issue. BioRegen is treated differently from BioChex: BioChex appears as a new lab presence with a virtual-office address, same-day domain/COA timing for a GLP3(R) document, no recognized accreditation, and unresolved operator credentials. Its GLP3(R) COA is useful for confirming retatrutide, but not enough to establish arms-length testing.

Regulatory and promotion risk are live. No public FDA or FTC action against Oasis was found as of June 13, 2026, but its GLP catalog sits in the same enforcement climate as recently warned vendors. A Prof. Peptide coupon-code cluster and Instagram promotion amplify broad purity and third-party-testing claims beyond what Finnrick's product-level data supports.

Inside the full report:

  • Per-product Finnrick pass/fail analysis and methodology-divergence charts for all 4 tested products
  • Nevada filing exhibits, payment-terms linkage, and personnel background review
  • BioRegen versus BioChex COA integrity comparison, including the GLP3(R) retatrutide document
  • Certificate-transparency, Wayback, staging-subdomain, and privacy-policy leak exhibits
  • GLP3(R), Retatrutide, and Cagrilintide regulatory exposure analysis
  • Trustpilot merge artifacts, review-cluster notes, and affiliate/coupon-code promotion scan

Risk assessment

  • Product quality risk — CJC-1295 and BPC-157 — high: Finnrick data is product-specific: CJC-1295 records 0 pass / 3 fail with a 20.4% rating, and BPC-157 records 2 pass / 2 fail with a 49.59% rating.
  • BioChex COA-independence risk — high: BioChex has a virtual-office address, same-day domain/first Oasis COA timing, shared Hostinger/dns-parking pattern with the Oasis education site, no recognized accreditation, and unverified operator credentials.
  • Regulatory enforcement risk — high: Oasis markets GLP3(R)/Retatrutide, Cagrilintide, Semaglutide, and Tirzepatide under research-peptide framing in the same enforcement environment that produced 2026 FDA warning letters to comparable vendors.
  • Affiliate-promotion risk — medium: Prof. Peptide-network and coupon-site promotions use codes or referral-style links while making broad 99% purity and third-party-testing claims without clear disclosure in the scanned posts/pages.
  • Misleading history claims — medium: The About Us page says the company started in 2023, but AMD Research, LLC formed March 29, 2024 and myoasislabs.com registered November 25, 2024; a prior brand is suggested but unverified.
  • Unverified manufacturing-source risk — medium: No named manufacturer, ISO/cGMP facility identity, import record, or independently verifiable chain of custody was identified for the catalog.